116
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Content Validation of the ATTR Amyloidosis Patient Symptom Survey: Findings from Patient and Clinician Cognitive Debriefing Interviews

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 149-160 | Published online: 26 Aug 2020

References

  • Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451–2466. doi:10.1016/j.jacc.2015.09.075
  • Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107S112.
  • Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Ps. 2015;86(9):1036–1043. doi:10.1136/jnnp-2014-308724
  • Falk RH. Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques? Amyloid. 2012;19 Suppl 1:68–70. doi:10.3109/13506129.2012.674074
  • Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–239. doi:10.1080/07853890701842988
  • Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2):e000364. doi:10.1161/JAHA.111.000364
  • Milandri A, Farioli A, Gagliardi C, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020;22(3):507–515. doi:10.1002/ejhf.1742
  • Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–1300. doi:10.1161/CIRCULATIONAHA.111.078915
  • Falk RH, Dubrey SW. Amyloidosis heart disease. In: Gertz MA, Rajkumar SV, editors. Amyloidosis: Diagnosis and Treatment. New York (NY): Springer;2010. Contemporary Hematology.
  • Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106(10):528–540. doi:10.1016/j.acvd.2013.06.051
  • Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075. doi:10.1161/CIRCHEARTFAILURE.119.006075
  • Yarlas A, Gertz MA, Dasgupta NR, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019;60(2):169–175. doi:10.1002/mus.26515
  • Stewart M, Shaffer S, Murphy B, et al. Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018;7(2):349–364. doi:10.1007/s40120-018-0106-z
  • Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133(3):282–290. doi:10.1161/CIRCULATIONAHA.115.018852
  • Swiecicki PL, Zhen DB, Mauermann ML, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22(2):123–131. doi:10.3109/13506129.2015.1019610
  • Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7(3):497–508. doi:10.1089/dia.2005.7.497
  • Vinik EJ, Vinik AI, Paulson JF, et al. Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2014;19(2):104–114. doi:10.1111/jns5.12059
  • U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims; 2009. Available from: //www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed July 11, 2019.
  • Campanelli P. Testing survey questions: new directions in cognitive interviewing. B Sociol Methodol. 2016;55(1):5–17. doi:10.1177/075910639705500103
  • Farnik M, Pierzchała WA. Instrument development and evaluation for patient-related outcomes assessments. Patient Relat Outcome Meas. 2012;3:1–7. doi:10.2147/PROM.S14405
  • Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2–assessing respondent understanding. Value Health. 2011;14(8):978–988. doi:10.1016/j.jval.2011.06.013
  • Kucan L, Beck IL. Thinking aloud and reading comprehension research: inquiry, instruction, and social interaction. Rev Educ Res. 1997;67(3):271–299. doi:10.3102/00346543067003271
  • Amyloidosis Research Consortium. Advancing amyloidosis: a research roadmap; 2019. https://www.arci.org/wp-content/uploads/2019/03/ARC-White-Paper-Final-v3.pdf. Accessed August 26, 2019..